Homogenous TP53mut-associated tumor biology across mutation and cancer types revealed by transcriptome analysis
Open Access
- 14 April 2023
- journal article
- research article
- Published by Springer Nature in Cell Death Discovery
- Vol. 9 (1) , 1-14
Abstract
TP53 is the most frequently mutated gene in human cancer. While no TP53-targeting drugs have been approved in the USA or Europe so far, preclinical and clinical studies are underway to investigate targeting of specific or all TP53 mutations, for example, by restoration of the functionality of mutated TP53 (TP53mut) or protecting wildtype TP53 (TP53wt) from negative regulation. We performed a comprehensive mRNA expression analysis in 24 cancer types of TCGA to extract (i) a consensus expression signature shared across TP53 mutation types and cancer types, (ii) differential gene expression patterns between tumors harboring different TP53 mutation types such as loss of function, gain of function or dominant-negative mutations, and (iii) cancer-type-specific patterns of gene expression and immune infiltration. Analysis of mutational hotspots revealed both similarities across cancer types and cancer type-specific hotspots. Underlying ubiquitous and cancer type-specific mutational processes with the associated mutational signatures contributed to explaining this observation. Virtually no genes were differentially expressed between tumors harboring different TP53 mutation types, while hundreds of genes were over- and underexpressed in TP53mut compared to TP53wt tumors. A consensus list included 178 genes that were overexpressed and 32 genes that were underexpressed in the TP53mut tumors of at least 16 of the investigated 24 cancer types. In an association analysis of immune infiltration with TP53 mutations in 32 cancer subtypes, decreased immune infiltration was observed in six subtypes, increased infiltration in two subtypes, a mixed pattern of decreased and increased immune cell populations in four subtypes, while immune infiltration was not associated with TP53 status in 20 subtypes. The analysis of a large cohort of human tumors complements results from experimental studies and supports the view that TP53 mutations should be further evaluated as predictive markers for immunotherapy and targeted therapies.Keywords
This publication has 77 references indexed in Scilit:
- More targets, more pathways and more clues for mutant p53Oncogenesis, 2013
- Drastic Effect of GermlineTP53Missense Mutations in Li-Fraumeni PatientsHuman Mutation, 2013
- Mutant p53: one name, many proteinsGenes & Development, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancerProceedings of the National Academy of Sciences, 2010
- Awakening guardian angels: drugging the p53 pathwayNature Reviews Cancer, 2009
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progressionNeuro-Oncology, 1999
- Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progressionNeuro-Oncology, 1999
- p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumorsOncogene, 1998